Living cells are ready for their close-ups, thanks to a new imaging technique that needs no dyes or other chemicals, yet renders high-resolution, three-dimensional, quantitative imagery of cells and their internal structures – all ...
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Takeda Pharmaceutical's new drug application (NDA) of Adcetris (brentuximab vedotin) 50mg intended to treat patients with CD30 positive relapsed or refractory hodgkin ...
Bayer HealthCare has failed to win the backing of the US FDA's Cardiovascular and Renal Drugs Advisory Committee to expand the use of its oral anticoagulant Xarelto (rivaroxaban) 2.5 mg twice daily (BID) in combination with standard ...
Tags: FDA Panel, ACS Patients
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare ...
Mallinckrodt (NYSE: MNK) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for PENNSAID® (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal ...
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Application ...
Tags: Iroko Pharmaceuticals, FDA, ZORVOLEX, osteoarthritis pain
Schistosoma mansoni and its close relatives are parasitic flatworms that affect millions worldwide and kill an estimated 250,000 people a year. A study published on January 16 in PLOS Pathogens identifies a new part of the molecular pathway ...
Tags: Consumer Electronics, Electronics
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Application ...
Sunesis Pharmaceuticals has expanded its hematology franchise through separate global licensing agreements for two preclinical kinase inhibitor programs. The first agreement, with Biogen Idec, is for global commercial rights to SNS-062, a ...
Tags: Sunesis Pharmaceuticals, Medicine
Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Mycophenolic Acid Delayed-release Tablets, 180 mg and 360 mg. This product is the generic version of Novartis' Myfortic® ...
A new combination of drugs might prolong life in certain older leukemia patients, a new study suggests. The research, led by German scientists, included nearly 800 older people (average age 73) who had been diagnosed with chronic ...
Tags: Drug, Drug Combo, Leukemia
Actavis plc (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a ...
What is Cryptosporidium parvum and where is it found? Cryptosporidium parvum is one of the most common enteropathogens to affect humans in the world. The protozoan parasite causes a gut infection referred to as cryptosporidiosis. The ...
Tags: Cryptosporidium parvum, protozoan parasite, gut infection
Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus® (formerly ...
Tags: Veloxis Pharmaceuticals, New Drug Application, Envarsus®
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option to conduct the investigational new drug (IND) enabling program and to submit an IND. ...
Tags: BioCryst, NIAID, investigational new drug, BCX4430, Marburg virus disease